Es­pe­ri­on shares bounce up on an ef­fec­tive triplet ap­proach to slash­ing LDL

Es­pe­ri­on shares $ES­PR got a bounce out of a Phase II up­date on a triple com­bi­na­tion drug us­ing be­mpe­doic acid in re­duc­ing LDL. A com­bi­na­tion ap­proach adding Ze­tia and Lip­i­tor to the ex­per­i­men­tal ther­a­py slashed LDL among sub­jects with hy­per­c­ho­les­terolemia by 64% from base­line, com­pared to a place­bo.

More than 9 out of 10 pa­tients had a greater than 50% re­duc­tion in LDL, keep­ing up with the biotech’s plans to be ready to launch new gener­ic/brand­ed com­pe­ti­tion that can of­fer a low-cost ap­proach to con­trol­ling LDL.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER